Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 5, 2015, Pages 675-683

  Krill, Lauren S ^a   Tewari, Krishnansu S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Bevacizumab; Chemotherapy; Recurrent cervical cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; PACLITAXEL; TOPOTECAN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; DISEASE FREE SURVIVAL; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; UTERINE CERVICAL NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; TOPOTECAN; UTERINE CERVICAL NEOPLASMS;

EID: 84924366746     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1010511     Document Type: Review

References (32)

1. American Cancer Society Statistics on Cervical Cancer. Available from: www.cancer.org. [Accessed 28 January 2015]
2. Wright JD, Viviano D, Powell MA, et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol 2006;103(2):489-93
3. Eskander RN, Tewari KS. Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. J Gynecol Oncol 2014;25(3):249-59
4. Tewari KS, Monk BJ. New strategies in cervical cancer: from angiogenesis blockade to immunotherapy. Clin Cancer Res 2014;20(21):5349-58
5. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358(19):2039-49
6. Dellas A, Moch H, Schultheiss E, et al. Angiogenesis in cervical neoplasia: microvessel quantitation in precancerous lesions and invasive carcinomas with clinicopathological correlations. Gynecol Oncol 1997;67(1):27-33
7. Dobbs SP, Hewett PW, Johnson IR, et al. Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia. Br J Cancer 1997;76(11):1410-15
8. Tjalma W, Sonnemans H, Weyler J, et al. Angiogenesis in cervical intraepithelial neoplasia and the risk of recurrence. Am J Obstet Gynecol 1999;181(3):554-9
9. Monk BJ, Willmott LJ, Sumner DA. Anti-angiogenesis agents in metastatic or recurrent cervical cancer. Gynecol Oncol 2010;116(2):181-6
10. Tewari KS, Sill MW, Long HJ III, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370(8):734-43
11. Tewari K, Monk BJ. Development of a platform for systemic antiangiogenesis therapy for advanced cervical cancer. Clin Adv Hematol Oncol 2014;12(11):1-12
12. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatincontaining doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27(28):4649-55
13. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004;22(15):3113-19
14. Long HJ III, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23(21):4626-33
15. Eskander RN, Tewari KS. Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer. Curr Opin Obstet Gynecol 2014;26(4):314-21
16. Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2009;27(7):1069-74
17. Jackson MW, Rusthoven CG, Fisher CM, Schefter TE. Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence. Onco Targets Ther 2014;7:751-9
18. Zighelboim I, Wright JD, Gao F, et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol 2013;130(1):64-8
19. Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2010;28(22):3562-9
20. Symonds P, Gourley C, Davidson S, et al. LBA25-PR-CIRCCa: A randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. Ann Oncol 2014;25(5):1-41
21. Moore KN, Herzog TJ, Lewin S, et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol 2007;105(2):299-303
22. Lorusso D, Petrelli F, Coinu A, et al. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol 2014;133(1):117-23
23. Kitagawa R, Katsumata N, Ando M, et al. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. Gynecol Oncol 2012;125(2):307-11
24. Saito I, Kitagawa R, Fukuda H, et al. A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). Jpn J Clin Oncol 2010;40(1):90-3
25. Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011;10(3):151-6
26. Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010;46(2):439-48
27. NCI Press Release. Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer. Available from: www.cancer.gov/newscenter/newsfromnci/2013/GOG240
28. NCCN Clinical Practice Guidelines in Oncology. Cervical Cancer Version 2. 2015. Available from: www.NCCN.org
29. Krill LS, Adelson JW, Randall LM, Bristow RE. Clinical commentary: medical ethics and the ramifications of equipoise in clinical research. Is a confirmatory trial using a nonbevacizumab containing arm feasible in patients with recurrent cervical cancer? Gynecol Oncol 2014;134(3):447-9
30. FDA approves Avastin to treat patients with aggressive and late-stage cervical cancer. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm410121.htm [14 August 2014]
31. Moore DH, Tian C, Monk BJ, et al. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2010;116(1):44-9
32. Tewari K, Sill MW, Moore DH, et al. High-risk patients with recurrent/advanced cervical cancer may derive the most benefit from anti-angiogenesis therapy: a Gynecologic Oncology Group study [SGO Women's Health Abstract 144]. Gynecol Oncol 2014;133(Suppl 1):S60